Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir

Stanley Zimba; Nyuma Mbewe; Lorraine Chishimba; Mashina Chomba; Deanna Saylor

doi:10.1177/0049475520953704

Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir

Stanley Zimba, Nyuma Mbewe, Lorraine Chishimba, Mashina Chomba, Deanna Saylor

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

In 2016, the World Health Organization adopted dolutegravir (DTG)-based antiretroviral therapy as an alternative first-line treatment of HIV after many clinical trials showed that it was more effective, better tolerated and more protective than efavirenz and boosted protease inhibitors against discontinuation of treatment from adverse drug reactions. However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.

Original language	English (US)
Pages (from-to)	216-218
Number of pages	3
Journal	Tropical Doctor
Volume	51
Issue number	2
DOIs	https://doi.org/10.1177/0049475520953704
State	Published - Apr 2021

Keywords

HIV
Tuberculosis
dolutegravir
immune reconstitution inflammatory syndrome

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1177/0049475520953704

Cite this

@article{6cc750138e8146c99447e3274aabc692,

title = "Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir",

abstract = "In 2016, the World Health Organization adopted dolutegravir (DTG)-based antiretroviral therapy as an alternative first-line treatment of HIV after many clinical trials showed that it was more effective, better tolerated and more protective than efavirenz and boosted protease inhibitors against discontinuation of treatment from adverse drug reactions. However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.",

keywords = "HIV, Tuberculosis, dolutegravir, immune reconstitution inflammatory syndrome",

author = "Stanley Zimba and Nyuma Mbewe and Lorraine Chishimba and Mashina Chomba and Deanna Saylor",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2021",

month = apr,

doi = "10.1177/0049475520953704",

language = "English (US)",

volume = "51",

pages = "216--218",

journal = "Tropical Doctor",

issn = "0049-4755",

publisher = "SAGE Publications Ltd",

number = "2",

}

TY - JOUR

T1 - Immune reconstitution inflammatory syndrome

T2 - a report of TB-IRIS after switching from efavirenz to dolutegravir

AU - Zimba, Stanley

AU - Mbewe, Nyuma

AU - Chishimba, Lorraine

AU - Chomba, Mashina

AU - Saylor, Deanna

N1 - Publisher Copyright: © The Author(s) 2020.

PY - 2021/4

Y1 - 2021/4

N2 - In 2016, the World Health Organization adopted dolutegravir (DTG)-based antiretroviral therapy as an alternative first-line treatment of HIV after many clinical trials showed that it was more effective, better tolerated and more protective than efavirenz and boosted protease inhibitors against discontinuation of treatment from adverse drug reactions. However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.

AB - In 2016, the World Health Organization adopted dolutegravir (DTG)-based antiretroviral therapy as an alternative first-line treatment of HIV after many clinical trials showed that it was more effective, better tolerated and more protective than efavirenz and boosted protease inhibitors against discontinuation of treatment from adverse drug reactions. However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.

KW - HIV

KW - Tuberculosis

KW - dolutegravir

KW - immune reconstitution inflammatory syndrome

UR - http://www.scopus.com/inward/record.url?scp=85090456549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090456549&partnerID=8YFLogxK

U2 - 10.1177/0049475520953704

DO - 10.1177/0049475520953704

M3 - Article

C2 - 32903146

AN - SCOPUS:85090456549

SN - 0049-4755

VL - 51

SP - 216

EP - 218

JO - Tropical Doctor

JF - Tropical Doctor

IS - 2

ER -

Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this